Multiple antigenic peptides as vaccine platform for the induction of humoral responses against dengue-2 virus

被引:22
作者
Amexis, Georgios [1 ]
Young, Neal S. [1 ]
机构
[1] NHLBI, Natl Inst Hlth, Hematol Branch, Bethesda, MD 20892 USA
关键词
D O I
10.1089/vim.2007.0029
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Dengue is an important agent of human disease for which no licensed vaccine is available to the public. We used multiple antigenic peptides (MAPS) as an antigen carrier for the development of subunit vaccines against dengue-2 virus (DEN-2). Commercially available software (MacVector (TM) 7.0) was used to identify potential antigenic B-cell epitopes of E-glycoprotein. A total of 60 BALB/c mice were immunized with 12 recombinant DEN-2-specific MAPS and the humoral immune response was assessed by anti-DEN-2 ELISA and PRNT50 assays. Anti-DEN-2 ELISA showed high levels of anti-DEN-2 antibodies and post-immune sera reduced viral infectivity and prevented infection of monkey kidney cells (LLC-MK2) with live DEN-2 virus. Seven neutralizing DEN-2 epitopes were identified that generated PRNT50 titers of up to 1:160. Our findings show that the MAP platform can be used as an antigen-presenting platform for dengue vaccine development.
引用
收藏
页码:657 / 663
页数:7
相关论文
共 41 条
  • [1] Basak A, 1995, J Pept Sci, V1, P385, DOI 10.1002/psc.310010606
  • [2] Chang Gwong-Jen J, 2004, Expert Rev Vaccines, V3, P199, DOI 10.1586/14760584.3.2.199
  • [3] Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells
    Crill, WD
    Roehrig, JT
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (16) : 7769 - 7773
  • [4] Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines
    Ghosh, S
    Jackson, DC
    [J]. INTERNATIONAL IMMUNOLOGY, 1999, 11 (07) : 1103 - 1110
  • [5] Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates
    Guirakhoo, F
    Pugachev, K
    Zhang, Z
    Myers, G
    Levenbook, I
    Draper, K
    Lang, J
    Ocran, S
    Mitchell, F
    Parsons, M
    Brown, N
    Brandler, S
    Fournier, C
    Barrere, B
    Rizvi, F
    Travassos, A
    Nichols, R
    Trent, D
    Monath, T
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (09) : 4761 - 4775
  • [6] Guzman Maria G, 2004, Expert Rev Anti Infect Ther, V2, P895, DOI 10.1586/14789072.2.6.895
  • [7] Halstead Scott B, 2005, Vaccine, V23, P849, DOI 10.1016/j.vaccine.2004.03.069
  • [8] Different Approaches to Potentiate the Immune Response Induced by a 12-Mer Synthetic Peptide
    Haro, I.
    Gomara, M. J.
    [J]. CURRENT PROTEIN & PEPTIDE SCIENCE, 2000, 1 (02) : 125 - 137
  • [9] Liposome entrapment and immunogenic studies of a synthetic lipophilic multiple antigenic peptide bearing VP1 and VP3 domains of the hepatitis A virus:: a robust method for vaccine design
    Haro, I
    Pérez, S
    García, M
    Chan, WC
    Ercilla, G
    [J]. FEBS LETTERS, 2003, 540 (1-3) : 133 - 140
  • [10] Hombach J, 2005, VACCINE, V23, P5205, DOI [10.1016/j.vaccine.2005.07.002, 10.1016/j.vaccine.2004.11.040]